NCT04868981View on ClinicalTrials.gov

Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

February 23, 2022

Study Completion Date

March 14, 2022

Conditions
Hepatitis B
Interventions
DRUG

GST-HG141 tablets

Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

DRUG

Matching Placebos for GST-HG141 tablets

Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

Trial Locations (1)

130000

The first hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
lead

Fujian Cosunter Pharmaceutical Co. Ltd

INDUSTRY

NCT04868981 - Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets | Biotech Hunter | Biotech Hunter